Attempt to Establish Prognostic Predictive System for Hepatocellular Carcinoma Using Artificial Intelligence for Assistance with Selection of Treatment Modality.
Journal
Liver cancer
ISSN: 2235-1795
Titre abrégé: Liver Cancer
Pays: Switzerland
ID NLM: 101597993
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
14
12
2022
accepted:
06
03
2023
medline:
7
12
2023
pubmed:
7
12
2023
entrez:
7
12
2023
Statut:
epublish
Résumé
Because of recent developments in treatments for hepatocellular carcinoma (HCC), methods for determining suitable therapy for initial or recurrent HCC have become important. This study used artificial intelligence (AI) findings to establish a system for predicting prognosis of HCC patients at time of reoccurrence based on clinical data as a reference for selection of treatment modalities. As a training cohort, 5,701 observations obtained at the initial and each subsequent treatment for recurrence from 1,985 HCC patients at a single center from 2000 to 2021 were used. The validation cohort included 5,692 observations from patients at multiple centers obtained at the time of the initial treatment. An AI calculating system (PRAID) was constructed based on 25 clinical factors noted at each treatment from the training cohort, and then predictive prognostic values for 1- and 3-year survival in both cohorts were evaluated. After exclusion of patients lacking clinical data regarding albumin-bilirubin (ALBI) grade or tumor-node-metastasis stage of the Liver Cancer Study Group of Japan, 6th edition (TNM-LCSGJ 6th), ALBI-TNM-LCSGJ 6th (ALBI-T) and modified ALBI-T scores confirmed that prognosis for patients in both cohorts was similar. The area under the curve for prediction of both 1- and 3-year survival in the validation cohort was 0.841 (sensitivity 0.933 [95% CI: 0.925-0.940], specificity 0.517 [95% CI: 0.484-0.549]) and 0.796 (sensitivity 0.806 [95% CI: 0.790-0.821], specificity 0.646 [95% CI: 0.624-0.668]), respectively. The present PRAID system might provide useful prognostic information related to short and medium survival for decision-making regarding the best therapeutic modality for both initial and recurrent HCC cases.
Identifiants
pubmed: 38058420
doi: 10.1159/000530078
pii: 530078
pmc: PMC10697750
doi:
Types de publication
Journal Article
Langues
eng
Pagination
565-575Informations de copyright
© 2023 The Author(s). Published by S. Karger AG, Basel.
Déclaration de conflit d'intérêts
Atsushi Hiraoka, MD, PhD, received lecture fees from Chugai, Bayer, and Eli Lilly. None of the other authors have potential conflicts of interest to declare.
Références
Hepatobiliary Surg Nutr. 2020 Aug;9(4):530-533
pubmed: 32832511
Liver Cancer. 2017 Jun;6(3):204-215
pubmed: 28626732
Nat Rev Clin Oncol. 2009 Jun;6(6):339-51
pubmed: 19399023
Hepatology. 2021 Jan;73 Suppl 1:158-191
pubmed: 32430997
Hepatol Int. 2017 Jul;11(4):317-370
pubmed: 28620797
Med Image Anal. 2012 Jul;16(5):933-51
pubmed: 22465077
Calcif Tissue Int. 2017 Apr;100(4):348-360
pubmed: 28197643
Gastroenterology. 2006 Aug;131(2):461-9
pubmed: 16890600
Hepatol Int. 2022 Jun;16(3):577-589
pubmed: 35352293
N Engl J Med. 2008 Jul 24;359(4):378-90
pubmed: 18650514
Am J Gastroenterol. 2012 Apr;107(4):569-77; quiz 578
pubmed: 22158026
Hepatol Res. 2015 Jan;45(2):
pubmed: 25625806
Nature. 2015 May 28;521(7553):436-44
pubmed: 26017442
Radiology. 2015 May;275(2):599-608
pubmed: 25559235
Nature. 2017 Feb 2;542(7639):115-118
pubmed: 28117445
Radiology. 2010 Sep;256(3):806-16
pubmed: 20720069
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Gastroenterology. 2014 Jun;146(7):1691-700.e3
pubmed: 24583061
Liver Cancer. 2019 Oct;8(5):403-411
pubmed: 31768348
Am J Surg. 1995 Jun;169(6):589-94
pubmed: 7771622
J Clin Oncol. 2015 Feb 20;33(6):550-8
pubmed: 25512453
Lancet. 2018 Mar 24;391(10126):1163-1173
pubmed: 29433850
Ann Surg. 2011 Oct;254(4):569-76
pubmed: 21892074
Liver Cancer. 2017 Nov;6(4):325-336
pubmed: 29234636
Hepatol Res. 2008 Jan;38(1):37-51
pubmed: 18039202
Lancet Oncol. 2021 Jul;22(7):991-1001
pubmed: 34051880
Liver Cancer. 2015 Mar;4(1):39-50
pubmed: 26020028
J Hepatol. 2022 Mar;76(3):681-693
pubmed: 34801630
Hepatology. 2004 Dec;40(6):1396-405
pubmed: 15565571
Liver Cancer. 2021 Jun;10(3):181-223
pubmed: 34239808
Cancers (Basel). 2022 Mar 09;14(6):
pubmed: 35326554
Aust N Z J Psychiatry. 2020 Feb;54(2):123-126
pubmed: 31707786
PLoS One. 2018 Mar 7;13(3):e0194085
pubmed: 29513742
Front Bioeng Biotechnol. 2022 May 23;10:872044
pubmed: 35677305
J Hepatol. 2012 Aug;57(2):399-420
pubmed: 22633836
Nature. 2001 Nov 1;414(6859):105-11
pubmed: 11689955
J Gastroenterol Hepatol. 2016 May;31(5):1031-6
pubmed: 26647219
Sci Rep. 2019 May 30;9(1):7704
pubmed: 31147560
Molecules. 2016 Jul 28;21(8):
pubmed: 27483216
Eur J Radiol. 2021 Sep;142:109834
pubmed: 34252866
Hepatology. 2005 Nov;42(5):1208-36
pubmed: 16250051
J Diabetes Sci Technol. 2016 May 03;10(3):730-6
pubmed: 26555782
Radiology. 2011 Dec;261(3):834-44
pubmed: 21998047
J Clin Gastroenterol. 2013 Jul;47 Suppl:S2-6
pubmed: 23632345
Cancers (Basel). 2022 Nov 10;14(22):
pubmed: 36428616